Novel therapies for the “treatment of agitation” and disease-modifying therapies will help drive up the annual growth rate in Alzheimer’s disease drugs to 20% over a period of 10 years from 2020, according to an analysis by GlobalData. The market in eight of the world’s major economies, including the US and UK, was worth $2.2 billion in 2020 but is expected to be worth $13.7 billion in 2030. GlobalData says the main contributors to growth will be the launch of 23 “pipeline products”, including monoclonal antibody treatments like aducanumab and lecanemab, which have both demonstrated a degree of success in slowing cognitive decline. Similar treatments like Lilly’s donanemab and retemetug are expected in the next few years, GlobalData adds, forecasting that lecanemab and donanemab will become “the top-selling Alzheimer’s disease drugs by 2030,” generating sales in the eight major economies of $3.5 billion and $2 billion respectively in 2030.
